NOVC.DE Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (14 нояб. 2023 @ 18:35):

Stats
Объем за сегодня	26 806.00
Средний объем	51 037.00
Рыночная капитализация	406.69B
EPS	€8.63 ( 2023-06-30 )
Last Dividend	€3.00 ( 2023-08-18 )
Next Dividend	€0 ( N/A )
P/E	22.91
ATR14	€2.62 (2.86%)

Объем Корреляция

Длинно: 0.32 (neutral)

Кратко: -0.73 (moderate negative)

Signal:(48.651) Neutral

Novo Nordisk A/S Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Novo Nordisk A/S Корреляция - Валюта/Сырье

0.01
( neutral )

0.42
( neutral )

-0.28
( neutral )

-0.57
( weak negative )

0.38
( neutral )

0.87
( strong )

Novo Nordisk A/S Финансовые показатели

Annual	2022
Выручка:	€176.95B
Валовая прибыль:	€148.51B (83.92 %)
EPS:	€24.51

FY	2022
Выручка:	€176.95B
Валовая прибыль:	€148.51B (83.92 %)
EPS:	€24.51

FY	2021
Выручка:	€140.80B
Валовая прибыль:	€117.14B (83.20 %)
EPS:	€20.79

FY	2020
Выручка:	€126.95B
Валовая прибыль:	€106.01B (83.51 %)
EPS:	€18.05

Financial Reports:

No articles found.

Novo Nordisk A/S Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€4.25 (N/A)	€0 (N/A)	€8.15 (N/A)	€0 (N/A)	€3.00 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Novo Nordisk A/S Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 6.14 - average (71.63%) | Divividend Growth Potential Score: 4.38 - Stable (12.49%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.670	2002-03-13
Last Dividend	€3.00	2023-08-18
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	30	--
Total Paid Out	€100.58	--
Avg. Dividend % Per Year	0.00%	--
Score	2.88	--
Div. Sustainability Score	6.14
Div.Growth Potential Score	4.38
Div. Directional Score	5.26	--

Next Divdend (Est)
(2025-02-26)

€2.78 Estimate 6.71 %

Dividend Stability

0.27 Very Poor

Dividend Score

2.88

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
IC1B.F	Ex Dividend Junior	2023-08-31	Annually	0.00%
SYZ.DE	Ex Dividend Junior	2023-07-12	Annually	0.00%
CIS.DE	Ex Dividend Knight	2023-10-03	Quarterly	0.00%
LLY.DE	Ex Dividend Knight	2023-08-14	Quarterly	0.00%
VOS.DE	Ex Dividend Junior	2023-05-25	Sporadic	0.00%
EBA.DE	Ex Dividend Knight	2023-08-31	Quarterly	0.00%
NVD.DE	Ex Dividend Knight	2023-09-06	Quarterly	0.00%
8GM.DE	Ex Dividend Knight	2023-08-31	Semi-Annually	0.00%
GDX.DE	Ex Dividend Knight	2023-10-05	Quarterly	0.00%
R66.DE	Ex Dividend Knight	2023-08-17	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.351	1.500	2.98	4.47	[0 - 0.5]
returnOnAssetsTTM	0.251	1.200	1.635	1.962	[0 - 0.3]
returnOnEquityTTM	0.869	1.500	1.460	2.19	[0.1 - 1]
payoutRatioTTM	0.422	-1.000	5.78	-5.78	[0 - 1]
currentRatioTTM	0.824	0.800	-0.880	-0.704	[1 - 3]
quickRatioTTM	0.635	0.800	-0.971	-0.777	[0.8 - 2.5]
cashRatioTTM	0.175	1.500	-0.141	-0.211	[0.2 - 2]
debtRatioTTM	0.0884	-1.500	8.53	-10.00	[0 - 0.6]
interestCoverageTTM	-18.83	1.000	-8.08	-8.08	[3 - 30]
operatingCashFlowPerShareTTM	23.78	2.00	2.07	4.15	[0 - 30]
freeCashFlowPerShareTTM	17.38	2.00	1.308	2.62	[0 - 20]
debtEquityRatioTTM	0.285	-1.500	8.86	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.841	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.392	1.000	4.16	4.16	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.01	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.715	0.800	8.57	6.85	[0.5 - 2]
Total Score				6.14

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	40.52	1.000	6.01	0	[1 - 100]
returnOnEquityTTM	0.869	2.50	4.51	2.19	[0.1 - 1.5]
freeCashFlowPerShareTTM	17.38	2.00	4.21	2.62	[0 - 30]
dividendYielPercentageTTM	0.440	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	23.78	2.00	2.07	4.15	[0 - 30]
payoutRatioTTM	0.422	1.500	5.78	-5.78	[0 - 1]
pegRatioTTM	0.142	1.500	-2.38	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.496	1.000	0.0917	0	[0.1 - 0.5]
Total Score				4.38

Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.